Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with previously announced plan to reduce general and administrative expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-commercial and non-medical headcount, primarily at the Netherlands headquarters. The company said, “We remain on track to reduce total G&A expenses by 15% or $10M annually and anticipate one-time restructuring costs of approximately $7M to be recorded in the fourth quarter of 2025 in connection with the headcount reduction.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
- Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment
- Pharming Group Joins Euronext AMX® Index Reflecting Growth Momentum
- Pharming Group Appoints Kenneth Lynard as CFO Amid Strong Financial Performance
- = Pharming Group NV ADS trading resumes
